Physician profile
Robert Amjad Ali
NPI 1629414768
$10,154.47
in general payments reported to CMS, 2019-2025
66 companies · $3,062 in 2025
The $3,062 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,069 · 2020: $633 · 2021: $787 · 2022: $602 · 2023: $791 · 2024: $3,211 · 2025: $3,062.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,743 · Education: $322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,742.90 |
| Education | $321.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,003.11 | 2019-2025 | Lynparza, Tagrisso, Imfinzi |
| Janssen Biotech, INC. | $815.78 | 2019-2025 | Tecvayli, Darzalex, Erleada |
| Novartis Pharmaceuticals Corporation | $691.23 | 2019-2025 | |
| Seagen INC. | $483.13 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $443.73 | 2019-2025 | Opdivo, Opdualag, Reblozyl |
| Daiichi Sankyo INC. | $403.46 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Pfizer INC. | $370.19 | 2019-2025 | |
| Amgen INC. | $369.22 | 2019-2023 | Kyprolis |
| Merck Sharp & Dohme LLC | $366.74 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Celgene Corporation | $336.63 | 2019-2025 | Reblozyl |
| Incyte Corporation | $311.87 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Takeda Pharmaceuticals U.S.A., INC. | $304.23 | 2020-2025 | Fruzaqla, Ninlaro, Alunbrig |
| Exelixis INC. | $299.69 | 2019-2025 | Cabometyx |
| Genzyme Corporation | $220.09 | 2019-2025 | |
| Gilead Sciences, INC. | $208.99 | 2021-2025 | Trodelvy |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $189.51 | 2019-2025 | Verzenio, Jaypirca |
| Eisai INC. | $160.42 | 2020-2025 | |
| Janssen Scientific Affairs, LLC | $149.84 | 2022-2025 | Talvey, Tecvayli, Darzalex |
| Puma Biotechnology, INC. | $148.97 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $141.12 | 2020-2025 | |
| Abbvie INC. | $125.41 | 2022-2025 | |
| Sobi, INC | $121.02 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $116.37 | 2021-2025 | |
| Array Biopharma INC | $115.18 | 2020-2025 | Braftovi, Mektovi, Tukysa |
| Tersera Therapeutics LLC | $115.14 | 2024-2025 | Zoladex |
| Glaxosmithkline, LLC. | $114.51 | 2020-2025 | Ojjaara |
| Servier Pharmaceuticals LLC | $112.36 | 2024-2025 | |
| Beigene USA, INC. | $111.07 | 2020-2025 | Brukinsa, Tevimbra |
| Stemline Therapeutics INC. | $108.10 | 2024-2025 | Orserdu |
| Blueprint Medicines Corporation | $107.68 | 2024-2025 | Ayvakit |
| Regeneron Healthcare Solutions, INC. | $98.98 | 2020-2024 | Libtayo |
| Kite Pharma, INC. | $97.23 | 2024-2025 | Yescarta |
| Springworks Therapeutics, INC. | $96.91 | 2024-2025 | Ogsiveo |
| Astellas Pharma US INC | $89.97 | 2020-2025 | Xtandi |
| Foundation Medicine, INC. | $76.80 | 2019 | |
| Pharmacosmos Therapeutics INC. | $75.73 | 2024-2025 | Monoferric |
| Tempus Ai, INC | $74.31 | 2024-2025 | Xt Cdx |
| Emd Serono, INC. | $72.37 | 2022-2025 | |
| Genmab U.S., INC. | $60.73 | 2024-2025 | Tivdak, Epkinly |
| Mirati Therapeutics, INC. | $58.53 | 2023-2024 | Krazati |
| Alexion Pharmaceuticals, INC. | $55.94 | 2024 | Ultomiris |
| Pharmaessentia USA Corporation | $55.55 | 2024-2025 | Besremi |
| Genentech USA, INC. | $47.68 | 2024-2025 | Polivy, Columvi, Lunsumio |
| Janssen Pharmaceuticals, INC | $45.77 | 2021 | |
| Karyopharm Therapeutics INC. | $45.54 | 2021-2025 | Xpovio |
| Epizyme, INC. | $42.42 | 2021 | |
| Agios Pharmaceuticals, INC. | $40.38 | 2024-2025 | Pyrukynd |
| Iovance Biotherapeutics, INC. | $40.17 | 2025 | Amtagvi |
| Ipsen Biopharmaceuticals, INC | $39.38 | 2024-2025 | Onivyde |
| Dova Pharmaceuticals | $32.05 | 2019-2021 | |
| Taiho Oncology, INC. | $31.33 | 2024 | |
| Immunocore Limited | $31.06 | 2025 | Kimmtrak |
| Adaptive Biotechnologies Corporation | $28.76 | 2024 | Clonoseq |
| Axonics, INC. | $27.64 | 2022-2023 | Axonics |
| Pharmacyclics LLC, An Abbvie Company | $27.11 | 2020 | |
| Geron Corporation | $21.27 | 2025 | Rytelo |
| Grifols USA, LLC | $21.26 | 2019 | |
| Legend Biotech USA INC. | $20.79 | 2025 | Carvykti |
| Acrotech Biopharma INC. | $20.35 | 2022 | |
| Spectrum Pharmaceuticals INC. | $20.03 | 2024 | Rolvedon |
| Novocure INC. | $19.55 | 2025 | Optune Lua (Novottf-200t) |
| Sun Pharmaceutical Industries INC. | $19.14 | 2020 | |
| Beone Medicines USA, INC. | $17.93 | 2025 | Tevimbra |
| Allergan, INC. | $16.66 | 2020 | |
| Adc Therapeutics America, INC. | $14.01 | 2024 | |
| Rigel Pharmaceuticals, INC. | $6.35 | 2023 | Rezlidhia, Tavalisse |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.